propranolol has been researched along with shikonin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chen, Z; Geng, Y; Huang, S; Li, M; Li, Y; Liu, X; Wang, X; Wu, H; Yang, E; Zhang, D | 1 |
2 other study(ies) available for propranolol and shikonin
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Shikonin reverses pyruvate kinase isoform M2-mediated propranolol resistance in infantile hemangioma through reactive oxygen species-induced autophagic dysfunction.
Topics: Adrenergic beta-Antagonists; Animals; Endothelial Cells; Hemangioma; Propranolol; Pyruvate Kinase; Reactive Oxygen Species; Skin Neoplasms; Treatment Outcome | 2023 |